[Regenerative medicine for heart failure].
Heart failure is one of the most important cardiovascular health problems throughout the world and has high mortality, and there is a need to develop more effective therapeutic strategies to replace such specialized treatment as mechanical circulatory support and cardiac transplantation. Mesenchymal stem cells (MSC) are multipotent plastic-adherent cells obtained from bone marrow, adipose tissue, and other tissues and can be easily expanded in culture. MSC exert their role in cardiac regeneration not only by differentiating into specific cell types such as cardiomyocytes and vascular endothelial cells but also through paracrine effects via secretion of angiogenic and antiapoptotic factors. On the basis of information obtained from basic and translational research, several clinical trials have recently been started to evaluate the safety and efficacy of autologous MSC for heart failure.
Nagaya
Noritoshi
N
Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute.
Kitamura
Soichiro
S
D017209:Apoptosis; D001854:Bone Marrow Cells / Q000166:cytology; D002454:Cell Differentiation; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism; D032383:Myocytes, Cardiac; D018919:Neovascularization, Physiologic; D014182:Transplantation, Autologous
D036341:Intercellular Signaling Peptides and Proteins